Abstract
Background Sensorineural hearing impairment (SNHI) is a common disorder with a significant genetic component. Genetic testing for SNHI often involves next-generation sequencing (NGS), but SNHI-related pathogenic STRC variants cannot be directly addressed by conventional NGS due to the complex genomic scenario derived from large genomic rearrangements and a highly homologous pseudogene. Long-read sequencing (LRS) offers an unprecedented resolution to these challenges.
Methods We developed a comprehensive workflow that integrates the PacBio-based LRS approach with marker-mediated refinements to effectively address pseudogene contamination. This methodology was applied to analyze the STRC gene in a cohort of 100 unrelated Taiwanese patients diagnosed with SNHI of unknown genetic cause after first-tier NGS testing.
Results We identified bi-allelic STRC variants in 11 patients (11% diagnostic yield), including homozygous deletions, compound heterozygous deletions and conversions, and compound heterozygous SNVs and CNVs. In total, we detected STRC variants in 27 patients, with 81.6% of these variants occurring in patients with mild to moderate SNHI.
Conclusions This study represents the first large-scale clinical investigation utilizing LRS technology for the genetic diagnosis of SNHI. Our study highlights the diagnostic capabilities of LRS in detecting complex variants within the STRC and advancing our understanding of the genetic etiology of SNHI that remains unresolved by conventional NGS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by National Science and Technology Council of the Executive Yuan of Taiwan (NSTC 110-2314-B-002-189-MY3, Chen-Chi Wu), National Health Research Institutes grant (NHRI-EX111-10914PI, Chen-Chi Wu), National Taiwan University Hospital & National Taiwan University Joint Program grants (111-UN0048, Chen-Chi Wu & Jacob Shu-Jui Hsu), and National Taiwan University Hospital Hsin-Chu Branch & National Health Research Institutes Joint Program grant (NHRI-113-B02, Chen-Chi Wu & Shih-Feng Tsai)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of National Taiwan University Hospital gave ethical approval for this work. (202012083RIND)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The resultant datasets in this study are included within the article. Full datasets are available from the corresponding authors upon reasonable request.
